Last reviewed · How we verify
NCT06594185
A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract Extraction
NA trial testing enVista Aspire EA or Aspire Toric ETA IOLs in Cataract in 335 participants. Completed in 21 May 2025.
21 May 2025
Quick facts
| Lead sponsor | Bausch & Lomb Incorporated |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 335 |
| Start date | 29 August 2024 |
| Primary completion | 21 May 2025 |
| Estimated completion | 21 May 2025 |
| Sites | 62 locations across United States |
Drugs / interventions tested
- enVista Aspire EA or Aspire Toric ETA IOLs
Conditions studied
- Cataract — all drugs for Cataract →
Sponsor
Bausch & Lomb Incorporated — full company profile →
Who can join
22 and older, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study to evaluate the real-world clinical performance of the enVista Aspire and Aspire Toric intraocular lens (IOL) models EA and ETA and to assess surgeon and subject satisfaction
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06594185
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cataract
Currently open trials in the same condition.
- NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
- NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
- NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
- NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
- NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
Other Bausch & Lomb Incorporated trials
Trials by the same sponsor.
- NCT07054606 — A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear · Phase 4 · completed
- NCT06803654 — A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Rel · Phase 3 · completed
- NCT06479148 — Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens · NA · terminated
- NCT06333028 — A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction · completed
- NCT06346340 — A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06594185 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bausch & Lomb Incorporated
- Last refreshed: 10 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06594185.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing